Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Adipocyte-derived leucine aminopeptidase
(
A-LAP
) is a novel zinc-metallopeptidase involved in angiotensin II (AngII) metabolism, cell migration and antigen presentation. These functions are implicated in the progression of cancer, whereas
A-LAP
expression and involvement have not been studied in any type of cancer. We investigated the expression of
A-LAP
in
endometrial cancer
as well as its association with angiogenesis and clinicopathological features. Immunohistochemical staining of 58 endometrial endometrioid adenocarcinoma specimens revealed that 37 were
A-LAP
immunoreactive. We also found that
A-LAP
staining correlated with histological tumor grade in a significant and reverse manner. In addition, serum CA-125 levels in patients with
A-LAP
positive cancers were significantly higher. However, contrary to our hypothesis that
A-LAP
suppresses angiogenic activity via AngII metabolism,
A-LAP
expression was not associated with the microvessel count determined by CD34 immunostaining. Our results suggest that
A-LAP
is involved in
endometrial cancer
cell growth and differentiation. However, further studies, especially of the biological roles of
A-LAP
, are required to confirm this notion.
...
PMID:Expression of adipocyte-derived leucine aminopeptidase in endometrial cancer. Association with tumor grade and CA-125. 1465 15
